THIS CONVERTIBLE PROMISSORY NOTE HAS BEEN ACQUIRED FOR INVESTMENT PURPOSES ONLY
AND NOT FOR DISTRIBUTION AND MAY BE TRANSFERRED OR OTHERWISE DISPOSED OF ONLY IN
COMPLIANCE WITH THE SECURITIES ACT OF l933, AS AMENDED (THE “ACT”).
BIORESTORATIVE THERAPIES, INC.
_____________ __, 201_
CONVERTIBLE PROMISSORY NOTE

DUE __________ __, 2019

BIORESTORATIVE THERAPIES, INC., a Delaware corporation (the “Company”), hereby
promises to pay to ___________________________________________(the “Holder”) at
the offices of the Company, 40 Marcus Drive, Suite One, Melville, New York
11747, the principal sum of ________________________________________THOUSAND
DOLLARS ($___________) on ___________ __, 2019 (the “Maturity Date”) in such
coin or currency of the United States of America as at the time of payment shall
be legal tender for the payment of public and private debts and to pay interest
on said principal sum at the rate of fifteen percent (15%) per annum through the
Maturity Date.  Interest on the principal balance of this Promissory Note
(“Note”) from the date hereof shall be payable on the Maturity Date.

1. Registered Owner.  The Company may consider and treat the person in whose
name this Note shall be registered as the absolute owner thereof for all
purposes whatsoever (whether or not this Note shall be overdue) and the Company
shall not be affected by any notice to the contrary.  Subject to the provisions
hereof, the registered owner of this Note shall have the right to transfer it by
assignment and the transferee thereof, upon its registration as owner of this
Note, shall become vested with all the powers and rights of the transferor. 
Registration of any new owner shall take place upon presentation of this Note to
the Company at its offices together with the Note Assignment Form attached
hereto duly executed.  In case of transfers by operation of law, the transferee
shall notify the Company of such transfer and of its address, and shall submit
appropriate evidence regarding the transfer so that this Note may be registered
in the name of the transferee.  This Note is transferable only on the books of
the Company by the Holder on the surrender hereof, duly endorsed. Communications
sent to any registered owner shall be effective as against all holders or
transferees of this Note not registered at the time of sending the
communication.
2. Conversion.
2.1
Conversion Right.

2.1.1 Conversion Right.  Subject to the terms hereof, during the period
commencing on the date hereof and expiring at 5:00 P.M., New York City local
time, on the day immediately preceding the Maturity Date (the “Conversion
Period”), the Holder shall have the right to convert, in whole or in part, the
then outstanding principal amount of this Note, together with accrued interest
thereon, into (a) shares of Common Stock, par value $.001 per share, of the
Company (“Conversion Stock”) at a conversion price of sixty cents ($0.60) per
share of Conversion Stock, subject to adjustment pursuant to the provisions of
Section 2.2 (the “Conversion Price”) and (b) a warrant in the form attached
hereto as Exhibit 1 (the “Warrant”) to purchase such number of shares of Common
Stock, par value $.001 per share, of the Company equal to the number of shares
of Conversion Stock issued upon the conversion of principal hereunder.

--------------------------------------------------------------------------------

2.1.2 Exercise of Conversion Right.  The foregoing conversion privilege may be
exercised during the Conversion Period by the delivery by the Holder to the
Company by facsimile or other electronic transmission of an election to
convert.  Upon delivery by the Holder of its notice of election to convert, this
Note shall be deemed cancelled and, subject to, and effective upon, the Holder’s
delivery of this Note to the Company for cancellation, the Holder shall be
deemed to be the holder of record of the shares of Conversion Stock and the
Warrant issuable upon such conversion, notwithstanding that the stock transfer
books of the Company shall then be closed or that certificates representing the
Conversion Stock and the Warrant shall not then be actually delivered to the
Holder.

2.2
Anti-Dilution Provisions.

2.2.1 Adjustments for Stock Dividends; Combinations, Etc.  In case the Company
shall do any of the following (an “Event”):

(i) declare a dividend or other distribution on its Common Stock payable in
Common Stock of the Company,

(ii) subdivide the outstanding Common Stock pursuant to a stock split or
otherwise,

(iii) combine the outstanding Common Stock  into a smaller number of shares
pursuant to a reverse split or otherwise, or

(iv) reclassify its Common Stock,

then the Conversion Price in effect at the time of the record date for such
dividend or other distribution or of the effective date of such subdivision,
combination or reclassification shall be adjusted to give effect to such Event. 
Each such adjustment of the Conversion Price shall be calculated to the nearest
one-hundredth of a cent.  Such adjustment shall be made successively whenever
any Event listed above shall occur.

2.2.2 Adjustment for Reorganization, Consolidation or Merger.  In case of any
reorganization of the Company (or any other entity, the securities of which are
at the time receivable on the conversion of this Note) after the date hereof or
in case after such date the Company (or any such other entity) shall consolidate
with or merge with or into another entity, then, and in each such case, the
Holder of this Note upon the conversion thereof as provided in Section 2.1
hereof at any time after the consummation of such reorganization, consolidation
or merger, shall be entitled to receive, in lieu of the securities and property
receivable upon the conversion of this Note prior to such consummation, the
securities or property to which such Holder would have been entitled upon such
consummation if the conversion of this Note had occurred immediately prior
thereto, all subject to further adjustment as provided in Section 2.2.1; in each
such case, the terms of this Note shall be applicable to the securities or
property receivable upon the conversion of this Note after such consummation.
The Company shall provide the Holder with at least ten (10) business days prior
written notice of any reorganization, consolidation or merger described in this
Section 2.2.2.

--------------------------------------------------------------------------------

2.3 Reservation of Shares.  During the period within which this Note may be
converted, the Company shall, at all times, reserve and keep available out of
its authorized capital stock, solely for the purposes of issuance upon
conversion of this Note, such number of its shares of Common Stock as shall be
issuable upon the conversion of this Note (including such number of shares of
Common Stock as shall be issuable upon exercise of the Warrant issuable upon
conversion of this Note); and if at any time the number of shares of authorized
Common Stock shall not be sufficient to effect the conversion of this Note, the
Company will take such corporate action as may be necessary to increase its
authorized but unissued  shares of Common Stock to such number of shares as
shall be sufficient for such purpose; the Company shall have analogous
obligations with respect to any other securities or property issuable upon
conversion of this Note.

2.4 Fractional Shares.  The Company shall not be required to issue certificates
representing fractions of shares, nor shall it be required to issue scrip or pay
cash in lieu of fractional interests, it being the intent of the Company and the
Holder that all fractional interests shall be eliminated.

2.5 Rights of the Holder.  The Holder shall not, by virtue hereof, be entitled
to any rights of a shareholder of the Company, either at law or in equity, and
the rights of the Holder are limited to those expressed in this Note.

3. Events of Default.  If (a) the Company shall fail to pay the outstanding
principal balance of this Note, and accrued interest thereon, on the Maturity
Date; (b) the Company shall make a general assignment for the benefit of
creditors; (c) the Company shall be adjudicated a bankrupt or insolvent; (d) the
Company shall file a voluntary petition in bankruptcy or a petition or an answer
seeking an arrangement with creditors; (e) the Company shall take advantage of
any bankruptcy, insolvency or readjustment of debt law or statute or file an
answer admitting the material allegations of a petition filed against it in any
proceeding under any such law; (f) the Company shall apply for or consent to the
appointment of a receiver, trustee or liquidator for all or substantially all of
its assets; or (g) the Company shall have an involuntary case commenced against
it under the Federal bankruptcy laws, which case is not dismissed or stayed
within sixty (60) days (each an “Event of Default”), then, at any time
thereafter and unless such Event of Default shall have been cured or shall have
been waived in writing by the Holder, the Holder may, by written notice to the
Company, declare the entire unpaid principal amount of this Note then
outstanding, together with accrued interest thereon, to be forthwith due and
payable, whereupon the same shall become forthwith due and payable.
4. Costs of Collection.  If an Event of Default shall occur, the Company shall
pay, in addition to the unpaid principal amount of this Note, together with
accrued interest thereon, default interest at a rate of twenty percent (20%) per
annum effective upon the occurrence of the Event of Default (in lieu of the
fifteen percent (15%) per annum provided for herein) and the costs and expenses
incurred in effecting collection hereunder, including reasonable attorneys’
fees.

--------------------------------------------------------------------------------

5. Investment Intent. The Holder, by its acceptance hereof, hereby represents
and warrants that this Note is being acquired for investment purposes only and
without a view to the distribution thereof, and may be transferred only in
compliance with the Act.
6. Transfer to Comply with the Securities Act of l933.  This Note may not be
sold or otherwise disposed of except as follows: (a) to a person or entity to
whom this Note may legally be transferred without registration and without the
delivery of a current prospectus under the Act with respect thereto; or (b) to
any person or entity upon delivery of a prospectus then meeting the
require-ments of the Act relating to such securities and the offering thereof
for such sale or disposition, and thereafter to all successive assignees.
7. Lost, Stolen or Destroyed Note.  In the event that the Holder notifies the
Company that this Note has been lost, stolen or destroyed and provides (a) a
letter, in form satisfactory to the Company, to the effect that it will
indemnify the Company from any loss incurred by it in connection therewith,
and/or (b) an indemnity bond in such amount as is reasonably required by the
Company, the Company having the option of electing either (a) or (b) or both,
the Company may, in its sole discretion, accept such letter and/or indemnity
bond in lieu of the surrender of this Note as required by the terms hereof.
8. Notices.  All notices required hereunder, except as provided for in Section
2, shall be given by first-class mail, postage prepaid, or overnight mail or
courier and, if given by the Holder addressed to the Company at 40 Marcus Drive,
Suite One, Melville, New York 11747, Attention: Secretary, or such other address
as the Company may designate in writing to the Holder; and if given by the
Company, addressed to the Holder at the address of the Holder shown on the books
of the Company.
9. Applicable Law; Jurisdiction.  This Note is issued under, and shall for all
purposes be governed by and construed in accordance with, the laws of the State
of New York, excluding choice of law principles thereof. The Company and, by its
acceptance of this Note, the Holder hereby irrevocably consent and submit to the
exclusive jurisdiction of any federal or state court located within Nassau or
Suffolk County, New York over any dispute arising out of or relating to this
Note and each party hereby irrevocably agrees that all claims in respect of such
dispute or any legal action related thereto shall be heard and determined in
such courts.  Each of the Company and the Holder hereby irrevocably waives, to
the fullest extent permitted by applicable law, any objection that it or he may
now or hereafter have to the laying of venue of any such dispute brought in such
court or any defense of inconvenient forum for the maintenance of such dispute.
10. Interpretation.  The Company and, by its acceptance of this Note, the Holder
acknowledge that they have been represented by counsel, or afforded the
opportunity to be represented by counsel, in connection with this Note.
Accordingly, any rule of law or any legal decision that would require the
interpretation of any claimed ambiguities in this Note against the party that
drafted it has no application and is expressly waived by the Company and the
Holder.  The provisions of this Note shall be interpreted in a reasonable manner
to give effect to the intent of the Company and the Holder.

--------------------------------------------------------------------------------

11. Miscellaneous.  This Note evidences the entire obligation of the Company
with respect to the payment of the principal amount hereof and the other matters
provided for herein.  No provision of this Note may be modified except by an
instrument in writing signed by the Company and the Holder.  Payment of the
outstanding principal amount of this Note, together with accrued interest
thereon, shall be made to the registered Holder of this Note on or after the
Maturity Date contemporaneous with and upon presentation of this Note for
payment.  No interest shall be due on this Note for such period of time that may
elapse between the Maturity Date and its presentation for payment.
[Remainder of page intentionally left blank]

--------------------------------------------------------------------------------

IN WITNESS WHEREOF, the Company has caused this Note to be signed on its behalf,
in its corporate name, by its duly authorized officer, all as of the day and
year first above written.
BIORESTORATIVE THERAPIES, INC.

By: 
      Mark Weinreb
      Chief Executive Officer

--------------------------------------------------------------------------------

BIORESTORATIVE THERAPIES, INC.

NOTE ASSIGNMENT FORM

 FOR VALUE RECEIVED, the undersigned _____________________________ (please print
or typewrite name of assignor) hereby sells, assigns and transfers unto
_________________________

(please print or typewrite name, address and social security or taxpayer
identification number, if any, of assignee) the within Promissory Note of
BioRestorative Therapies, Inc., dated ___________, 201_, in the original
principal amount of $_______ and hereby authorizes the Company  to transfer this
Note on its books.

TO BE COMPLETED BY INDIVIDUAL
HOLDER, JOINT TENANTS, TENANTS
IN COMMON OR AS HOLDERS OF
COMMUNITY PROPERTY
 

Name(s) of Holder(s) [Please Print]
 

Signature of Holder
 
  
Signature of Holder, if jointly held
 
 
  
Date
TO BE COMPLETED BY CORPORATE,

PARTNERSHIP, LIMITED LIABILITY
COMPANY OR TRUST HOLDER

Name of Holder [Please Print]
 
By: 
      Authorized Signatory
 
  
Name and Title of Authorized Signatory
[Please Print]
 
  
Date

Signature(s) Guaranteed:

--------------------------------------------------------------------------------

EXHIBIT 1
VOID AFTER 5:00 P.M., EASTERN TIME, ON ________________ ___, 202_
NEITHER THIS WARRANT NOR THE WARRANT STOCK (AS HEREINAFTER DEFINED) HAVE BEEN
REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE
SECURITIES LAWS OF ANY STATE.  THIS WARRANT AND THE WARRANT STOCK MAY BE
TRANSFERRED ONLY IN COMPLIANCE WITH THE ACT AND SUCH LAWS.  THIS LEGEND SHALL BE
ENDORSED UPON ANY WARRANT ISSUED IN EXCHANGE FOR THIS WARRANT.

--------------------------------------------------------------------------------

BIORESTORATIVE THERAPIES, INC.
(Incorporated under the laws of the State of Delaware)

Warrant

                                                                      

 _______ Shares

  ____________, 201_

FOR VALUE RECEIVED, BIORESTORATIVE THERAPIES, INC., a Delaware corporation (the
“Company”), hereby certifies that ___________________________________ (the
“Holder”) is entitled, subject to the provisions of this Warrant, to purchase
from the Company up to _____________________________________________ (_______)
SHARES OF COMMON STOCK, $.001 par value per share, of the Company (“Common
Shares”) at a price of EIGHTY CENTS ($0.80) per share (the “Exercise Price”)
during the period commencing on the date hereof and terminating at 5:00 P.M. on
the fifth anniversary of the date hereof.
The number of Common Shares to be received upon the exercise of this Warrant may
be adjusted from time to time as hereinafter set forth.  The Common Shares
deliverable upon such exercise, and as adjusted from time to time, are
hereinafter sometimes referred to as “Warrant Stock.”
The Holder agrees with the Company that this Warrant is issued, and all the
rights hereunder shall be held subject to, all of the conditions, limitations
and provisions set forth herein.
1. Exercise of Warrants.
1.1 Exercise.  Exercise of this Warrant shall be made upon surrender of this
Warrant with the Warrant Exercise Form attached hereto duly completed and signed
and delivered to the Company, at its address 40 Marcus Drive, Suite One,
Melville, New York 11747 (or such office or agency of the Company as it may
designate in writing to the Holder hereof).  Payment upon exercise shall be made
at the written option of the Holder either (i) in cash, wire transfer or by
certified or official bank check payable to the order of the Company equal to
the applicable aggregate Exercise Price, (ii) by the withholding of shares of
Warrant Stock otherwise issuable upon exercise of this Warrant, in accordance
with Section 1.2 or (iii) by a combination of either of the foregoing methods,
for the number of shares of Warrant Stock specified in such form (as such number
shall be adjusted to reflect any adjustment in the total number of shares of
Warrant Stock issuable to the Holder pursuant to the terms of this Warrant) and
the Holder shall thereupon be entitled to receive the number of duly authorized,
validly issued, fully-paid and non-assessable shares of Warrant Stock determined
as provided herein.  The Company shall promptly (but in no event later than five
(5) business days after the date on which the Company receives this Warrant, the
executed Warrant Exercise Form and payment of the Exercise Price, if any (the
“Exercise Date”)), issue or cause to be issued  and cause to be delivered to or
upon the written order of the Holder and in such name or names as the Holder may
designate (subject to the restrictions on transfer described in the legend set
forth on the face of this Warrant), a certificate for the shares of Warrant
Stock issuable upon such exercise, with such restrictive legend as required by
the Act, as applicable.  Subject to the delivery of this Warrant, the executed
Warrant Exercise Form and payment of the Exercise Price, if any, any person so
designated by the Holder to receive Warrant Stock shall be deemed to have become
the holder of record of such shares of Warrant Stock as of the Exercise Date. 
If this Warrant is exercised in part only, the Company shall, upon surrender of
this Warrant for cancellation, execute and deliver a new Warrant evidencing the
rights of the Holder hereof to purchase the balance of the shares purchasable
hereunder.

--------------------------------------------------------------------------------

1.2 Net Exercise.  If the Fair Market Value (as hereinafter defined) of one
Common Share is greater than the Exercise Price of one share of Warrant Stock
(at the date of calculation as set forth below), in lieu of exercising this
Warrant for cash, the Holder may elect to receive shares of Warrant Stock equal
to the number of Common Shares computed using the following formula:
X=Y*(A-B)/A
Where X= the number of Common Shares to be issued to the Holder
Y= the number of Common Shares purchasable under this Warrant or, if only a
portion of this Warrant is being exercised, the portion of this Warrant being
exercised (at the date of such calculation)
A= the Fair Market Value of one Common Share
B= the Exercise Price (as adjusted to the date of such calculation).
1.3 Fair Market Value.  For purposes hereof, “Fair Market Value” shall be
determined as follows:
(a) if the Common Shares of the Company are listed on any established stock
exchange or a national market system, including, without limitation, The Nasdaq
Stock Market, or quoted on any other market for which closing sales prices are
available, including, without limitation, the OTCQB, Fair Market Value shall be
the average of the closing sales prices for the Common Shares, as quoted on such
exchange, system or other market, on the five (5) trading days immediately
preceding the date on which the executed Warrant Exercise Form is delivered to
the Company;
(b) if the Common Shares of the Company are quoted but closing sales prices are
not reported, then Fair Market Value shall be the average of the mean between
the high bid and low asked prices for the Common Shares on the five (5) trading
days immediately preceding the date on which the executed Warrant Exercise Form
is delivered to the Company; or

--------------------------------------------------------------------------------

(c) in the absence of any quotations for the Common Shares of the Company during
the five (5) trading days immediately preceding the date on which the executed
Warrant Exercise Form is delivered to the Company, Fair Market Value shall be
determined in good faith by the Board of Directors of the Company.
2. Registered Owner.  The Company may consider and treat the person in whose
name this Warrant shall be registered as the absolute owner thereof for all
purposes whatsoever and the Company shall not be affected by any notice to the
contrary.  Subject to the provisions hereof, the registered owner of this
Warrant shall have the right to transfer it by assignment and the transferee
thereof, upon his registration as owner of this Warrant, shall become vested
with all the powers and rights of the transferor.  Registration of any new owner
shall take place upon presentation of this Warrant to the Company at its offices
together with the Warrant Assignment Form attached hereto duly executed.  In
case of transfers by operation of law, the transferee shall notify the Company
of such transfer and of his address, and shall submit appropriate evidence
regarding the transfer so that this Warrant may be registered in the name of the
transferee.  This Warrant is transferable only on the books of the Company by
the Holder on the surrender hereof, duly endorsed. Communications sent to any
registered owner shall be effective as against all holders or transferees of
this Warrant not registered at the time of sending the communication.
3. Reservation of Shares.  During the period within which the rights represented
by this Warrant may be exercised, the Company shall, at all times, reserve and
keep available out of its authorized capital stock, solely for the purposes of
issuance upon exercise of this Warrant, such number of its Common Shares as
shall be issuable upon the exercise of this Warrant; and if at any time the
number of authorized Common Shares shall not be sufficient to effect the
exercise of this Warrant, the Company will take such corporate action as may be
necessary to increase its authorized but unissued Common Shares to such number
of shares as shall be sufficient for such purpose; the Company shall have
analogous obligations with respect to any other securities or property issuable
upon exercise of this Warrant.
4. Fractional Shares.  The Company shall not be required to issue certificates
representing fractions of Common Shares, nor shall it be required to issue scrip
or pay cash in lieu of fractional interests, it being the intent of the Company
and the Holder that all fractional interests shall be eliminated.
5. Rights of the Holder.  The Holder shall not, by virtue hereof, be entitled to
any voting or other rights of a stockholder of the Company, either at law or in
equity, and the rights of the Holder are limited to those expressed in this
Warrant.
6. Anti‑Dilution Provisions.
6.1 Adjustments for Stock Dividends; Combinations, Etc.  (a) In case the Company
shall do any of the following (an “Event”):
(i) declare a dividend or other distribution on its Common Shares payable in
Common Shares of the Company,
(ii) subdivide the outstanding Common Shares pursuant to a stock split or
otherwise,

--------------------------------------------------------------------------------

(iii) combine the outstanding Common Shares into a smaller number of shares
pursuant to a reverse split or otherwise, or
(iv) reclassify its Common Shares,
then the Exercise Price in effect at the time of the record date for such
dividend or other distribution or of the effective date of such subdivision,
combination or reclassification shall be changed to a price determined by
dividing (a) the product of the number of Common Shares outstanding immediately
prior to such Event, multiplied by the Exercise Price in effect immediately
prior to such Event by (b) the number of Common Shares outstanding immediately
after such Event.  Each such adjustment of the Exercise Price shall be
calculated to the nearest one-hundredth of a cent.  Such adjustment shall be
made successively whenever any Event listed above shall occur.

(b) Whenever the Exercise Price is adjusted as set forth in Section 6.1 (whether
or not the Company then or thereafter elects to issue additional Warrants in
substitution for an adjustment in the number of shares of Warrant Stock), the
number of shares of Warrant Stock specified in each Warrant which the Holder may
purchase shall be adjusted, to the nearest full share, by multiplying such
number of shares of Warrant Stock immediately prior to such adjustment by a
fraction, of which the numerator shall be the Exercise Price immediately prior
to such adjustment and the denominator shall be the Exercise Price immediately
thereafter.
6.2 Adjustment for Reorganization, Consolida-tion or Merger.  In case of any
reorganization of the Company (or any other entity, the securities of which are
at the time receivable on the exercise of this Warrant) after the date hereof or
in case after such date the Company (or any such other -entity) shall
consolidate with or merge with or into another entity, then, and in each such
case, the Holder of this Warrant upon the exercise thereof as provided in
Section l at any time after the consummation of such reorganization,
consolidation or merger, shall be entitled to receive, in lieu of the securities
and property receivable upon the exercise of this Warrant prior to such
consummation, the securities or property to which such Holder would have been
entitled upon such consummation if such Holder had exercised this Warrant
immediately prior thereto, all subject to further adjustment as provided in
Section 6.l; in each such case, the terms of this Warrant shall be applicable to
the securities or property receivable upon the exercise of this Warrant after
such consummation. The Company shall provide the Holder with at least ten (10)
business days prior written notice of any reorganization, consolidation or
merger described in this Section 6.2.
7. Investment Intent.  Unless, prior to the exercise of this Warrant, the
issuance of the Warrant Stock has been registered with the Securities and
Exchange Commission pursuant to the Act, the Warrant Exercise Form shall be
accompanied by the Investment Representation Letter attached hereto, duly
executed by the Holder.
8. Restrictions on Transfer.
8.1 Transfer to Comply with the Securities Act of 1933.  Neither this Warrant
nor any Warrant Stock may be sold, assigned, transferred or otherwise disposed
of except as follows:  (1) to a person who, in the opinion of counsel reasonably
satisfactory to the Company, is a person to whom this Warrant or the Warrant
Stock may legally be transferred without registration and without the delivery
of a current prospectus under the Act with respect thereto and then only against
receipt of an agreement of such person to comply with the provisions of this
Section 8 with respect to any resale, assignment, transfer or other disposition
of such securities; or (2) to any person upon delivery of a prospectus then
meeting the requirements of the Act relating to such securities and the offering
thereof for such sale, assignment, transfer or disposition.

--------------------------------------------------------------------------------

8.2 Legend.  Subject to the terms hereof, upon exercise of this Warrant and the
issuance of the Warrant Stock, all certificates representing such Warrant Stock
shall bear on the face or reverse thereof substantially the following legend:
“THE SHARES EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”).  NO TRANSFER, SALE, ASSIGNMENT,
PLEDGE, HYPOTHECATION, OPTION, LOAN OR OTHER DISPOSITION OF THE SHARES EVIDENCED
BY THIS CERTIFICATE MAY BE MADE EXCEPT (A) PURSUANT TO AN EFFECTIVE REGISTRATION
STATEMENT UNDER THE ACT OR (B) IF THE COMPANY HAS BEEN FURNISHED WITH A
REASONABLY SATISFACTORY OPINION OF COUNSEL FOR THE HOLDER THAT SUCH TRANSFER,
SALE, ASSIGNMENT, PLEDGE, HYPOTHECATION OR OTHER DISPOSITION IS EXEMPT FROM THE
PROVISIONS OF SECTION 5 OF THE ACT OR THE RULES AND REGULATIONS IN EFFECT
THEREUNDER, AND IN COMPLIANCE WITH PROVISIONS OF APPLICABLE STATE SECURITIES
LAWS.”
9. Lost, Stolen or Destroyed Warrant.  In the event that the Holder notifies the
Company that this Warrant has been lost, stolen or destroyed and provides (a) a
letter, in form reasonably satisfactory to the Company, to the effect that it
will indemnify the Company from any loss incurred by it in connection therewith,
and/or (b) an indemnity bond in such amount as is reasonably required by the
Company, the Company having the option of electing (in its discretion) either
(a) or (b) or both, the Company shall accept such letter and/or indemnity bond
in lieu of the surrender of this Warrant as required by Section 1 hereof.
10. Notices.  All notices required hereunder shall be given by first-class mail,
postage prepaid, or overnight mail or courier and, if given by the Holder
addressed to the Company at 40 Marcus Drive, Suite One, Melville, New York
11747, Attention: Chief Executive Officer, or such other address as the Company
may designate in writing to the Holder; and if given by the Company, addressed
to the Holder at the address of the Holder shown on the books of the Company.
11. Applicable Law; Jurisdiction.  This Warrant is issued under, and shall for
all purposes be governed by and construed in accordance with, the laws of the
State of Delaware, excluding choice of law principles thereof. The Company and,
by its acceptance of this Warrant, the Holder hereby irrevocably consent and
submit to the exclusive jurisdiction of any federal or state court located
within Nassau or Suffolk County, New York over any dispute arising out of or
relating to this Warrant and each party hereby irrevocably agrees that all
claims in respect of such dispute or any legal action related thereto shall be
heard and determined in such courts.  Each of the Company and the Holder hereby
irrevocably waives, to the fullest extent permitted by applicable law, any
objection that it or he may now or hereafter have to the laying of venue of any
such dispute brought in such court or any defense of inconvenient forum for the
maintenance of such dispute.

--------------------------------------------------------------------------------

12. Amendments; Waivers.  This Warrant shall not be changed, modified or amended
except by a writing signed by the party to be charged, and this Warrant may not
be discharged except by performance in accordance with its terms or by a writing
signed by the party to be charged.
13. Interpretation.  The Holder, by its acceptance of this Warrant, acknowledges
that it has been represented by counsel, or afforded the opportunity to be
represented by counsel, in connection with this Warrant.  Accordingly, any rule
of law or any legal decision that would require the interpretation of any
claimed ambiguities in this Warrant against the party that drafted it has no
application and is expressly waived by the Holder.  The provisions of this
Warrant shall be interpreted in a reasonable manner to give effect to the intent
of the Company and the Holder.

[Remainder of page intentionally left blank.  Signature page follows.]

--------------------------------------------------------------------------------

IN WITNESS WHEREOF, the Company has caused this Warrant to be signed on its
behalf, in its corporate name, by its duly authorized officer, all as of the day
and year first above written.

BIORESTORATIVE THERAPIES, INC.

By: 
       Mark Weinreb
      Chief Executive Officer

--------------------------------------------------------------------------------

BIORESTORATIVE THERAPIES, INC.
WARRANT EXERCISE FORM

To:  BIORESTORATIVE THERAPIES, INC.

The undersigned, pursuant to the provisions set forth in the attached Warrant,
dated ____________ __, 2019, hereby irrevocably elects to purchase (check
applicable box):

___
________ shares of the Common Stock covered by such Warrant; or
 
___
the maximum number of shares of Common Stock covered by such Warrant pursuant to
the cashless exercise procedure set forth therein.

The undersigned herewith makes payment of the full purchase price for such
shares of $_______ at the price per share provided for in such Warrant.  Such
payment takes the form of (check applicable box or boxes):

___
$__________ in lawful money of the United States; and/or
 
___
the cancellation of such portion of the attached Warrant as is exercisable for a
total of _______ shares of Common Stock (using a Fair Market Value of $_______
per share, or an aggregate Fair Market Value of $__________, for purposes of
this calculation);

 
 
TO BE COMPLETED BY INDIVIDUAL
HOLDER, JOINT TENANTS, TENANTS
IN COMMON OR AS HOLDERS OF
COMMUNITY PROPERTY

Name(s) of Holder(s) [Please Print]
 
  
Signature of Holder
 
  
Signature of Holder, if jointly held
 
 
  
Address(es) of Holder(s)
 
  
Social Security Number(s) of Holder(s)
 
  
Date
  
TO BE COMPLETED BY CORPORATE,

PARTNERSHIP, LIMITED LIABILITY
COMPANY OR TRUST HOLDER

Name of Holder [Please Print]
 
By: 
      Authorized Signatory
 
  
Name and Title of Authorized Signatory
[Please Print]
 
  
Address of Holder
 
  
Tax Identification Number of Holder
 
  
Date
 

Signature(s) must conform in all respects to the
name of the Holder on the face of the attached Warrant.

--------------------------------------------------------------------------------

BIORESTORATIVE THERAPIES, INC.
WARRANT ASSIGNMENT FORM

FOR VALUE RECEIVED, _________________________ hereby sells, assigns and
transfers unto _____________________________ (please type or print name of
assignee) with an address at
______________________________________________________________ the right to
purchase shares of Common Stock of BIORESTORATIVE THERAPIES, INC. (the
“Company”) represented by this Warrant dated as of _______________ __, 2019 to
the extent of ___________ shares and does hereby irrevocably constitute and
appoint ___________________ attorney to transfer the same on the books of the
Company with full power of substitution in the premises.

 

TO BE COMPLETED BY INDIVIDUAL
HOLDER, JOINT TENANTS, TENANTS
IN COMMON OR AS HOLDERS OF
COMMUNITY PROPERTY

Name(s) of Holder(s) [Please Print]
 
  
Signature of Holder
 
  
Signature of Holder, if jointly held
 
 
  
Date
 

TO BE COMPLETED BY CORPORATE,

PARTNERSHIP, LIMITED LIABILITY
COMPANY OR TRUST HOLDER
 

Name of Holder [Please Print]
 
By: 
      Authorized Signatory
 
  
Name and Title of Authorized Signatory
[Please Print]
 
  
Date

Signature(s) Guaranteed:

--------------------------------------------------------------------------------

BIORESTORATIVE THERAPIES, INC.
FORM OF INVESTMENT REPRESENTATION LETTER

BioRestorative Therapies, Inc.
40 Marcus Drive
Suite One
Melville, New York 11747

Gentlemen:

In connection with the acquisition of _______________ shares of Common Stock
(the “Shares”) of BIORESTORATIVE THERAPIES, INC., a Delaware corporation (the
“Company”), by the undersigned from the Company pursuant to the exercise of a
Warrant, dated as of _____________ __, 2019, the undersigned does hereby
represent and warrant to the Company as follows:
(a)
The undersigned represents and warrants that the Shares acquired by it are being
acquired for its own account, for investment purposes and not with a view to any
distribution within the meaning of the Securities Act of 1933, as amended (the
“Securities Act”).  The undersigned will not sell, assign, mortgage, pledge,
hypothecate, transfer or otherwise dispose of any of the Shares unless (i) a
registration statement under the Securities Act with respect thereto is in
effect and the prospectus included therein meets the requirements of Section 10
of the Securities Act, or (ii) the Company has received a written opinion of its
counsel that, after an investigation of the relevant facts, such counsel is of
the opinion that such proposed sale, assignment, mortgage, pledge,
hypothecation, transfer or disposition does not require registration under the
Securities Act or any state securities law.

(b)
The undersigned understands that the resale of the Shares is not, and is not
being, registered under the Securities Act and the Shares must be held
indefinitely unless they are subsequently registered thereunder or an exemption
from such registration is available.

(c)
The undersigned recognizes that the acquisition of the Shares involves a high
degree of risk and is suitable only for persons of adequate financial means who
have no need for liquidity with respect to the Shares in that (a) it may not be
able to liquidate the Shares in the event of emergency; (b) transferability is
extremely limited; and (c) it could sustain a complete loss of its investment.

(d)
The undersigned represents and warrants that it (a) is competent to understand
and does understand the nature of its investment; and (b) is able to bear the
economic risk of an acquisition of the Shares.

(e)
The undersigned represents and warrants that it is an “accredited investor,” as
such term is defined in Rule 501 of Regulation D promulgated under the
Securities Act.  The undersigned meets the requirements of at least one of the
suitability standards for an “accredited investor” as set forth on the
Accredited Investor Certification attached hereto.

(f)
The undersigned has reviewed the Company’s filings with the Securities and
Exchange Commission, including the risk factors set forth therein, and has been
afforded the opportunity to obtain such information regarding the Company as it
has reasonably requested to evaluate the merits and risks of the undersigned’s
investment in the Shares. No oral or written representations have been made or
oral information furnished to the undersigned or its advisers in connection with
the investment in the Shares.

(g)
The Warrant was issued pursuant to the conversion of a Convertible Promissory
Note, dated as of __________, 201_, in the principal amount of $_________ issued
by the Company to the undersigned (the “Note”).

(h)
The undersigned confirms that the representations and warranties set forth in
the Subscription Agreement pursuant to which the Note was issued are true and
correct as of the date hereof as if made on and as of the date hereof with
respect to the purchase of the Shares.

(i)
The undersigned acknowledges that counsel to the Company will be relying, and
may rely, upon the foregoing in connection with any opinion of counsel it may
give with regard to the issuance of the Shares by the Company to the
undersigned, and any subsequent transfer of the Shares by the undersigned, and
agrees to advise the Company and its counsel in writing in the event of any
change in any of the foregoing.

Very truly yours,

 

TO BE COMPLETED BY INDIVIDUAL
HOLDER, JOINT TENANTS, TENANTS
IN COMMON OR AS HOLDERS OF
COMMUNITY PROPERTY

Name(s) of Holder(s) [Please Print]
 
  
Signature of Holder
 
  
Signature of Holder, if jointly held
 
 
  
Date
 

TO BE COMPLETED BY CORPORATE,

PARTNERSHIP, LIMITED LIABILITY
COMPANY OR TRUST HOLDER

Name of Holder [Please Print]
 
By: 
      Authorized Signatory
 
  
Name and Title of Authorized Signatory
[Please Print]
 
  
Date

--------------------------------------------------------------------------------

BIORESTORATIVE THERAPIES, INC.

WARRANT EXERCISE

Accredited Investor Certification
(Initial the appropriate box(es))

The undersigned represents and warrants that it, he or she is an “accredited
investor” based upon the satisfaction of one or more of the following criteria:

_____
(1) he or she is a natural person who has a net worth or joint net worth with
his or her spouse in excess of $1,000,000 at the time of his or her purchase1;
or

_____
(2) he or she is a natural person who had an individual income in excess of
$200,000 in each of the two most recent years or a joint income with his or her
spouse in excess of $300,000 in each of those years and has a reasonable
expectation of reaching the same income level in the current year; or

_____
(3) he or she is a director or executive officer of the Company; or

_____
(4) it is either (a) a bank as defined in Section 3(a)(2) of the Securities Act
or a savings and loan association or other institution as defined in Section
3(a)(5)(A) of the Securities Act, whether acting in its individual or fiduciary
capacity, (b) a broker or dealer registered pursuant to Section 15 of the
Securities Exchange Act of 1934, (c) an insurance company as defined in Section
2(13) of the Securities Act, (d) an investment company registered under the
Investment Company Act of 1940 or a business development company as defined in
Section 2(a)(48) of such act, (e) a small business investment company licensed
by the United States Small Business Administration under Section 301(c) or (d)
of the Small Business Investment Act of 1958, (f) a plan established and
maintained by a state or its political subdivisions, or any agency or
instrumentality of a state or its political subdivisions, for the benefit of its
employees, if such plan has total assets in excess of $5,000,000 or (g) an
employee benefit plan within the meaning of Title I of the Employee Retirement
Income Security Act of 1974, if the investment decision is made by a plan
fiduciary, as defined in Section 3(21) of such act, which plan fiduciary is a
bank, savings and loan association, an insurance company or a registered
investment advisor, or if the employee benefit plan has total assets in excess
of $5,000,000 or, if a self-directed plan, with investment decisions made solely
by persons who otherwise meet these suitability standards; or

____________________
1 For purposes of calculating net worth:
(i)
The undersigned’s primary residence shall not be included as an asset;

(ii)   Indebtedness that is secured by the undersigned’s primary residence, up
to the estimated fair market value of the primary residence at the date hereof,
shall not be included as a liability (except that if the amount of such
indebtedness outstanding at the date hereof exceeds the amount outstanding 60
days before the date hereof, other than as a result of the acquisition of the
primary residence, the amount of such excess shall be included as a liability);
and
(iii)  Indebtedness that is secured by the undersigned’s primary residence in
excess of the estimated fair market value of the primary residence at the date
hereof shall be included as a liability.

--------------------------------------------------------------------------------

_____
(5) it is a private business development company as defined in Section
202(a)(22) of the Investment Advisers Act of 1940; or

_____
(6) it is an organization described in Section 501(c)(3) of the Internal Revenue
Code of 1986, as amended, a corporation, a Massachusetts or similar business
trust or a partnership not formed for the specific purpose of acquiring the
Shares offered hereby, with total assets in excess of $5,000,000; or

_____
(7) it is a trust, with total assets in excess of $5,000,000, not formed for the
specific purpose of acquiring the Shares, whose purchase is directed by a
sophisticated person who has such knowledge and experience in financial and
business matters that he or she is capable of evaluating the merits and risks of
the prospective investment; or

_____
(8) it is a corporation, partnership or other entity, and each and every equity
owner of such entity initials a separate Accredited Investor Certification
pursuant to which it, he or she certifies that it, he or she meets the
qualifications set forth in either (1), (2), (3), (4), (5), (6) or (7) above.

If the Warrant Holder is an INDIVIDUAL,
or if the Shares are being acquired as JOINT
TENANTS, as TENANTS IN COMMON, or
as COMMUNITY PROPERTY:
 
  
Name(s) of Warrant Holder
 
  
Signature of Warrant Holder
 
  
Signature, if jointly held
 
  
Date
If the Warrant Holder is a PARTNERSHIP,
CORPORATION, LIMITED LIABILITY
COMPANY or TRUST:
 
 
  
Name of Warrant Holder
 
By: 
      Signature of Authorized Representative
 
  
Name and Title of Authorized Representative
 
  
Date